SUBSCRIBE
SUBSCRIBE

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
1 North Waukegan Road
North Chicago, IL 60064
Tel: 1-800-255-5162
Visit website
Email Us
Stock Symbol: ABBV
Stock Exchange: NYSE
  • Featured Employer
NEWS
Pictured: AbbVie sign on a building/courtesy of Ad
Business
AbbVie, Alpine Agree to End Phase II Lupus Trial Early and Slash Option Exercise Fee
Under the companies’ agreement, a previously disclosed option exercise fee of $75 million has been reduced to $10 million and the remaining pre-option development milestone has been removed.
December 22, 2023
 · 
2 min read
 · 
Tyler Patchen
FDA
Casgevy vs. Lyfgenia: The Battle of the Sickle Cell Gene Therapies Has Begun
Friday’s FDA approval of Vertex-CRISPR’s Casgevy and bluebird bio’s Lyfgenia has immediately revealed startling differences between these two gene therapies: price and a black-box warning.
December 8, 2023
 · 
2 min read
 · 
Greg Slabodkin
Pictured: AbbVie Corporate Office/iStock, vzphotos
Deals
AbbVie Continues Buying Spree with $8.7B Cerevel Acquisition to Bolster Neuro
The deal, announced late Wednesday, will provide AbbVie with access to Cerevel Therapeutics’ pipeline of clinical-stage and preclinical candidates for psychiatric and neurological diseases.
December 7, 2023
 · 
2 min read
 · 
Tristan Manalac
Drug Development
ADC and GLP-1 Rocket Ride Continues as 2023 Comes to Close
AbbVie’s $10.1 billion ImmunoGen buy and Altimmune’s Phase II win demonstrate that the antibody-drug conjugate market is red hot in cancer and GLP-1 drugs for weight loss are an absolute craze.
December 1, 2023
 · 
3 min read
 · 
Greg Slabodkin
Pictured: AbbVie Corporate Office/iStock, vzphotos
Drug Development
AbbVie Gets Phase II NSCLC Win for ADC, Looks to Accelerated Approval
The company’s investigational c-Met protein directed antibody-drug conjugate showed a “compelling” overall response rate in patients with previously treated non-small cell lung cancer.
December 1, 2023
 · 
2 min read
 · 
Tyler Patchen
Update: AbbVie headquarters building in California
Deals
AbbVie Buys ImmunoGen in $10B Deal, Gains Access to ADC for Ovarian Cancer
Facing the loss of Humira revenues from biosimilar competition, AbbVie is looking to grow its pipeline by acquiring ImmunoGen and its antibody-drug conjugate Elahere, which was granted FDA accelerated approval last year.
November 30, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Cancer cell in the bloodstream/iStock, D
Drug Development
ASH Preview: Darzalex Faspro in Multiple Myeloma, Imbruvica-Venclexta in Mantle Cell Lymphoma
J&J, AbbVie, Genmab and Genentech are presenting new data at next month’s American Society of Hematology meeting on the therapeutic potential of their therapies in multiple myeloma and mantle cell lymphoma.
November 22, 2023
 · 
3 min read
 · 
Tristan Manalac
Chart showing rapid growth/iStock, Geerati
Biologics Projected to Keep Gaining Ground in Cancer Therapeutics Market
The market size for biologic oncology therapies will reach $786 billion by 2029, far outstripping small molecules, a GlobalData report predicts.
November 20, 2023
 · 
4 min read
 · 
Patience Asanga
Update: AbbVie headquarters building in California
Drug Development
AbbVie’s Migraine Drug Ubrelvy Scores Victory in Phase III Study
When given hours ahead of an expected episode, a late-stage study showed the preventive benefits of Ubrelvy in safely reducing moderate or severe headaches within 24 hours of treatment.
November 17, 2023
 · 
2 min read
 · 
Tristan Manalac
Load More
JOBS
View All Jobs at AbbVie
IN THE PRESS
BioMidwest
U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)
February 27, 2024
 · 
13 min read
Business
AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology
February 22, 2024
 · 
4 min read
Business
AbbVie Announces Appointment of Robert A. Michael as Chief Executive Officer
February 20, 2024
 · 
7 min read
BioMidwest
AbbVie Unveils New Data from Robust Gastroenterology Portfolio at the 19th Congress of European Crohn’s and Colitis Organisation (ECCO)
February 19, 2024
 · 
24 min read
Business
AbbVie Declares Quarterly Dividend - February 15, 2024
February 15, 2024
 · 
1 min read
Deals
AbbVie Completes Acquisition of ImmunoGen
February 12, 2024
 · 
8 min read
Business
Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases
February 6, 2024
 · 
3 min read
Business
AbbVie Reports Full-Year and Fourth-Quarter 2023 Financial Results
February 2, 2024
 · 
29 min read
Business
Enigma Biomedical Group - USA Signs License Agreement with AbbVie for Novel 4R Tau PET Imaging Biomarkers
January 18, 2024
 · 
2 min read
BioMidwest
AbbVie Launches PRODUODOPA® (foslevodopa/foscarbidopa) for People Living with Advanced Parkinson’s Disease in the European Union
January 9, 2024
 · 
16 min read
Load More